The Clinical Utility of Plasma Epstein-Barr Virus DNA Assays in Nasopharyngeal Carcinoma: The Dawn of a New Era?

Medicine (United States)

Volumn 94, Issue 20, 2015, Pages

  Zhang, Wenna ^a   Chen, Yupei ^a   Chen, Lei ^a   Guo, Rui ^a   Zhou, Guanqun ^a   Tang, Linglong ^a   Mao, Yanping ^a   Li, Wenfei ^a   Liu, Xu ^a   Du, Xiaojing ^a   Sun, Ying ^a   Ma, Jun ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA; DNA BINDING PROTEIN; H5R PROTEIN, VACCINIA VIRUS; VIRUS PROTEIN;

ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; DISTANT METASTASIS; DISTANT METASTASIS FREE SURVIVAL; DNA DETERMINATION; EPSTEIN BARR VIRUS; HUMAN; LOCAL FAILURE FREE SURVIVAL; LONG TERM SURVIVAL; META ANALYSIS; NASOPHARYNX CARCINOMA; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REFERENCE VALUE; SYSTEMATIC REVIEW; VIRAL CLEARANCE; BLOOD; COMPLICATION; EPSTEIN BARR VIRUS INFECTION; GENETICS; NASOPHARYNGEAL NEOPLASMS; OUTCOME ASSESSMENT; PROGNOSIS; VIROLOGY;

DNA, VIRAL; DNA-BINDING PROTEINS; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; NASOPHARYNGEAL NEOPLASMS; PATIENT OUTCOME ASSESSMENT; PROGNOSIS; VIRAL PROTEINS;

EID: 84940657046     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000845     Document Type: Article

References (33)

1. Wei WI, Sham JST. Nasopharyngeal carcinoma. Lancet. 2005;365:2041-2054.
2. Le QT, Jones CD, Yau TK, et al. A comparison study of different PCR assays in measuring circulating plasma epstein-Barr virus DNA levels in patients with nasopharyngeal carcinoma. Clin Cancer Res. 2005;11:5700-5707.
3. Pfister DG, Ang KK, Brizel DM, et al. Head and neck cancers, version 2. 2013. Featured updates to the NCCN guidelines. JNCCN. 2013;11:917-923.
4. Chan AT. Nasopharyngeal carcinoma. Ann Oncol. 2010;21 (suppl 7):vii308-312.
5. Cheng SH, Yen KL, Jian JJ, et al. Examining prognostic factors and patterns of failure in nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy: impact on future clinical trials. Int J Radiation Oncol Biol Phys. 2001;50:717-726.
6. Lo YM. Quantitative analysis of Epstein-Barr virus DNA in plasma and serum: applications to tumor detection and monitoring. Ann New York Acad Sci. 2001;945:68-72.
7. Chan AT, Lo YM, Zee B, et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst. 2002;94:1614-1619.
8. Leung SF, Chan KC, Ma BB, et al. Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma. Ann Oncol. 2014;25:1204-1208.
9. Leung SF, Zee B, Ma BB, et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol. 2006;24:5414-5418.
10. Lin JC, Wang WY, Liang WM, et al. Long-term prognostic effects of plasma epstein-Barr virus DNA by minor groove binder-probe real-time quantitative PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2007;68:1342-1348.
11. Wang WY, Twu CW, Chen HH, et al. Plasma EBV DNA clearance rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal carcinoma. Clin Cancer Res. 2010;16:1016-1024.
12. Chan KCA, Lo YMD. Circulating EBV DNA as a tumor marker for nasopharyngeal carcinoma. Semin Cancer Biol. 2002;12:489-496.
13. Lin JC, Chen KY, Wang WY, et al. Detection of Epstein-Barr virus DNA in the peripheral-blood cells of patients with nasopharyngeal carcinoma: relationship to distant metastasis and survival. J Clin Oncol. 2001;19:2607-2615.
14. An X, Wang FH, Ding PR, et al. Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy. Cancer. 2011;117:3750-3757.
15. Chan SC, Hsu CL, Yen TC, et al. The role of 18F-FDG PET/CT metabolic tumour volume in predicting survival in patients with metastatic nasopharyngeal carcinoma. Oral Oncol. 2013;49:71-78.
16. Chai SJ, Pua KC, Saleh A, et al. Clinical significance of plasma Epstein-Barr Virus DNA loads in a large cohort of Malaysian patients with nasopharyngeal carcinoma. J Clin Virol. 2012;55:34-39.
17. Hou X, Zhao C, Guo Y, et al. Different clinical significance of preand post-treatment plasma Epstein-Barr virus DNA load in nasopharyngeal carcinoma treated with radiotherapy. Clin Oncol. 2011;23:128-133.
18. Twu CW, Wang WY, Liang WM, et al. Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2007;67:130-137.
19. Wang WY, Twu CW, Chen HH, et al. Long-term survival analysis of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA levels. Cancer. 2013;119:963-970.
20. Wang WY, Twu CW, Lin WY, et al. Plasma Epstein-Barr virus DNA screening followed by (1)(8)F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting posttreatment failures of nasopharyngeal carcinoma. Cancer. 2011;117:4452-4459.
21. Mutirangura A, Pornthanakasem W, Theamboonlers A, et al. Epstein-Barr viral DNA in serum of patients with nasopharyngeal carcinoma. Clin Cancer Res. 1998;4:665-669.
22. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815-2834.
23. Hsu CL, Chang KP, Lin CY, et al. Plasma Epstein-Barr virus DNA concentration and clearance rate as novel prognostic factors for metastatic nasopharyngeal carcinoma. Head Neck. 2012;34:1064-1070.
24. Li SW, Wang H, Xiang YQ, et al. Prospective study of prognostic value of Raf kinase inhibitory protein and pretreatment plasma Epstein-Barr virus DNA for distant metastasis in locoregionally advanced nasopharyngeal carcinoma. Head Neck. 2013;35:579-591.
25. Chen WH, Tang LQ, Wang FW, et al. Elevated levels of plasma Ddimer predict a worse outcome in patients with nasopharyngeal carcinoma. BMC Cancer. 2014;14:583.
26. Tang LQ, Li CF, Chen QY, et al. High-sensitivity C-reactive protein complements plasma Epstein-Barr virus deoxyribonucleic acid prognostication in nasopharyngeal carcinoma: a large-scale retrospective and prospective cohort Study. Int J Radiat Oncol Biol Phys. 2014.
27. Wei W, Huang Z, Li S, et al. Pretreatment Epstein-Barr virus DNA load and cumulative cisplatin dose intensity affect long-term outcome of nasopharyngeal carcinoma treated with concurrent chemotherapy: experience of an institute in an endemic area. Oncol Res Treat. 2014;37:88-95.
28. Chen L, Hu C-S, Chen X-Z, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2012;13:163-171.
29. Chen YP, Wang ZX, Chen L, et al. A Bayesian network metaanalysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. Ann Oncol. 2015;26:205-211.
30. Le QT, Zhang Q, Cao H, et al. An international collaboration to harmonize the quantitative plasma Epstein-Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma. Clin Cancer Res. 2013;19:2208-2215.
31. Lo YM, Chan LY, Lo KW, et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res. 1999;59:1188-1191.
32. Lo YM, Leung SF, Chan LY, et al. Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. Cancer Res. 2000;60:2351-2355.
33. To EW, Chan KC, Leung SF, et al. Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma. Clin Cancer Res. 2003;9:3254-3259.